title: Macrolides for the treatment of chronic bacterial prostatitis: an effective application of their unique pharmacokinetic and pharmacodynamic profile (Review).
abstract: Chronic bacterial prostatitis (CBP) is a persistent infection of the prostate characterized by poor quality of life mainly due to frequent relapse episodes caused by incomplete eradication of causative pathogens. Aggressive antibacterial therapy is required to attenuate the severe symptoms of CBP and to achieve a permanent cure. Although fluoroquinolones are currently recommended as first-choice agents, macrolide antibiotics are emerging as a noteworthy option for the treatment of CBP. Macrolide antibiotics are characterized by an impressive array of distinct pharmacokinetic (PK) and pharmacodynamic (PD) properties. These properties include high intracellular accumulation in phagocytes and at sites of infection, including the prostate; broad antibiotic but also biofilm-inhibiting properties; immunomodulating and inflammation-resolving activities. These features offer particular advantages for the treatment of chronic infections of the prostate gland, which are not easily amenable to drug therapy. Macrolides may be exploited to counteract the unsatisfactory rates of clinical symptom improvement and pathogen eradication. The results of a number of clinical trials support this proposal.
authors.affiliation: Department of Biomedical, Inf., Comm. and Env. Sciences, University of Insubria, Busto A, I-21052 Varese, Italy. gianpaolo.perletti@uninsubria.it
authors.forename: G
authors.initials: G
authors.lastname: Perletti
authors.forename: V
authors.initials: V
authors.lastname: Skerk
authors.forename: V
authors.initials: V
authors.lastname: Magri
authors.forename: A
authors.initials: A
authors.lastname: Markotic
authors.forename: S
authors.initials: S
authors.lastname: Mazzoli
authors.forename: M J
authors.initials: MJ
authors.lastname: Parnham
authors.forename: F M E
authors.initials: FM
authors.lastname: Wagenlehner
authors.forename: K G
authors.initials: KG
authors.lastname: Naber
mesh_terms: D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018441:Biofilms / Q000187:drug effects; D002986:Clinical Trials as Topic; D024881:Drug Resistance, Bacterial; D024841:Fluoroquinolones / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006090:Gram-Negative Bacteria / Q000502:physiology; D006094:Gram-Positive Bacteria / Q000502:physiology; D006801:Humans; D018942:Macrolides / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008297:Male; D011472:Prostatitis / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D018942:Macrolides